Newsbenzinga
Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says
· Published
Article summary
HSBC upgrades Gilead Sciences (GILD) to Buy, raising its price target to $155 on strong long-acting HIV & oncology potential.
An excerpt from the original article.
Comments —
Loading comments…